What were the actual revenue and EBITDA figures for Q2 2025, and how do they compare to consensus estimates? | PIII (Aug 14, 2025) | Candlesense
PIII

What were the actual revenue and EBITDA figures for Q2 2025, and how do they compare to consensus estimates?

Actual results vs. consensus

The P3 Health Partners Q2‑2025 press release does not disclose the specific revenue or EBITDA numbers—only that the company “executed on its $130 million EBITDA improvement plan” and that medical‑cost trends remained flat. Because the release omits the dollar amounts, we cannot quote the actual revenue or EBITDA figures, nor we can directly compare them to Wall‑Street consensus estimates (which analysts had previously pegged at roughly $XX million in revenue and $YY million in EBITDA for the quarter).

Trading implications

  • If the company’s results turn out to be in line with or ahead of the $130 million EBITDA target and the revenue run‑rate is at or above consensus, the beat would likely reinforce the bullish narrative around the cost‑management plan and could trigger a short‑term rally. Traders could look for upside momentum on the daily chart—especially if the stock is holding above its 20‑day moving average and breaking through recent resistance near the $X‑level. A breakout with volume would be a cue to consider buying on pull‑backs or adding to existing long positions.

  • If the actual figures fall short of the $130 million EBITDA goal or miss the consensus revenue estimate, the market may view the flat cost trend as insufficient to offset growth shortfalls, prompting a downside move. In that scenario, defensive positioning—such as tightening stops near the 20‑day moving average or taking a modest short‑biased stance—could be prudent, particularly if the price breaks below the 10‑day trendline and the relative strength index (RSI) dips into the sub‑30 territory.

Until the full numbers are released, the safest approach is to stay on the sidelines with a tight watch on the upcoming earnings call, monitor pre‑market price action for any surprise moves, and be ready to act quickly once the actual revenue and EBITDA figures are known.

Other Questions About This News

Is there any updated guidance for revenue, EBITDA, or EPS for the rest of 2025? How does the reported $130 million EBITDA improvement plan compare to prior guidance and what are the updated expectations for Q3 and FY2025? What specific headwinds impacted the prior period and are they expected to recur in upcoming quarters? Did the company achieve its medical cost trend goal of staying flat, and how does that compare to industry benchmarks? What is the current cash position and debt maturity profile following the Q2 results? How did the core business segments (e.g., Medicare Advantage, Medicaid) perform individually, and what are the growth trends? What impact will the Q2 results have on the company’s valuation multiples relative to peers? Are there any significant changes to the company's capital allocation strategy (e.g., share buybacks, dividend, M&A) following the results? How does P3’s performance and cost management compare to its main competitors in the population health management space?